Winnie Fong et al. (17) reported that Lactobacillus gallinarum-derived metabolites increased the effectiveness of anti-PD1 therapy in patients with CRC by suppressing regulatory T cells. The gene discussed is PDCD1; the disease is colorectal carcinoma.